Posts

SAMSHA: Treatment for Stimulant Use Disorders (2021)

This Treatment Improvement Protocol (TIP) reviews what is currently known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine (MA) and the misuse of prescribed stimulants (such as those for the treatment of attention defcit hyperactivity disorder [ADHD]). Read more

Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations

The Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations outline a public health response for 5 key populations (men who have sex with men, trans and gender diverse people, sex workers, people who inject drugs and people in prisons and other closed settings). They present and discuss new recommendations and consolidate a range of recommendations and guidance from current WHO guidelines. Read more

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in Canada

For people with opioid use disorder who are not responding to oral opioid agonist treatment, evidence supports the effectiveness of injectable opioid agonist treatment with injectable hydromorphone (an opioid analgesic) and diacetylmorphine (pharmaceutical grade heroin). While this treatment is effective at reducing illicit opioid use, concurrent cocaine use is prevalent. Dextroamphetamine (a central nervous system stimulant) has been found to be a safe and effective treatment for cocaine dependence among people receiving injectable opioid agonist treatment in Europe. Read more

Tuberculosis

Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. Tuberculosis is curable and preventable. Read more